PRELIMINARY PHASE 1 PHARMACOKINETIC (PK) AND EXPOSURE-RESPONSE (ER) ANALYSES RESULTS OF ABBV-085, AN ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED SOLID TUMORS.

Polepally A.; Gopalakrishnan S.; Robinson R.; Myzak M.; Demetri G.; Villalobos V.; Menon R.; Kasichayanula S.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >PRELIMINARY PHASE 1 PHARMACOKINETIC (PK) AND EXPOSURE-RESPONSE (ER) ANALYSES RESULTS OF ABBV-085, AN ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED SOLID TUMORS.

【24h】

PRELIMINARY PHASE 1 PHARMACOKINETIC (PK) AND EXPOSURE-RESPONSE (ER) ANALYSES RESULTS OF ABBV-085, AN ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED SOLID TUMORS.

机译：初步阶段1药代动力学（PK）和曝光 - 反应（ER）分析ABBV-085，ABBV-085的结果，抗体药物缀合物（ADC），高级实体瘤患者。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2020年第s1期|共1页
作者
Polepally A.; Gopalakrishnan S.; Robinson R.; Myzak M.; Demetri G.; Villalobos V.; Menon R.; Kasichayanula S.;
展开▼
作者单位

AbbVie Biotherapeut Redwood City CA USA;

AbbVie Ludwigshafen Germany;

AbbVie Biotherapeut Redwood City CA USA;

AbbVie Biotherapeut Redwood City CA USA;

Harvard Dana Farber Canc Inst Boston MA USA;

Univ Colorado Aurora CO USA;

AbbVie N Chicago IL 60064 USA;

AbbVie Biotherapeut Redwood City CA USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. PRELIMINARY PHASE 1 PHARMACOKINETIC (PK) AND EXPOSURE-RESPONSE (ER) ANALYSES RESULTS OF ABBV-085, AN ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED SOLID TUMORS. [J] . Polepally A., Gopalakrishnan S., Robinson R., Clinical Pharmacology and Therapeutics . 2020,第S1期

机译：初步阶段1药代动力学（PK）和曝光 - 反应（ER）分析ABBV-085，ABBV-085的结果，抗体药物缀合物（ADC），高级实体瘤患者。
2. PHARMACOKINETICS (PK) OF ANTI-MSLN ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH UNRESECTABLE PANCREATIC OR PLATINUM-RESISTANT OVARIAN CANCER IN A PHASE I STUDY. [J] . Samineni D., Li C., Nazzal D., Clinical Pharmacology and Therapeutics . 2015,第S1期

机译：在第一阶段研究中，患有无法治疗的胰腺癌或铂耐药性卵巢癌的患者中抗MSLN抗体药物结合物（ADC）的药代动力学（PK）。
3. PHARMACOKINETICS AND EXPOSURE-RESPONSE ANALYSES OF TELISOTUZUMAB VEDOTIN IN PATIENTS WITH ADVANCED SOLID TUMORS: PRELIMINARY PHASE I RESULTS. [J] . Parikh A., Menon R., Afar D., Clinical Pharmacology and Therapeutics . 2019,第Suppla1期

机译：先进实体瘤患者Telisotuzumab Vedotin的药代动力学和暴露 - 反应分析：初步阶段I结果。
4. Method Development of a novel PK assay for antibody-conjugated drug measurement of ADCs using peptide-linker-drug analyte [C] . Suk-Joon Hyung, Neelima Koppada, Surinder Kaur, ASMS Conference on Mass Spectrometry and Allied Topics . 2016

机译：使用肽 - 接头 - 药物分析物进行抗体缀合药物测量的新型PK测定的方法开发
5. Investigating the Pharmacokinetics and Pharmacodynamics of Antibody-Drug Conjugates, T Cells and Bispecific Antibodies [D] . Khot, Antari . 2020

机译：调查抗体 - 药物缀合物，T细胞和双特异性抗体的药代动力学和药效学
6. Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC [O] . Isabel Figueroa, Doug Leipold, Steve Leong, 2018

机译：当在动物中评估更高剂量时抗体-药物偶联物（ADC）在人体内的非线性药代动力学预测受耐受性限制：使用抗CD33 ADC的案例研究
7. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. [O] . Strumberg Dirk, Clark Jeffrey W, Awada Ahmad, 2007

机译：索拉非尼的安全性，药代动力学和初步抗肿瘤活性：晚期难治性实体瘤患者的四项I期试验综述。

PRELIMINARY PHASE 1 PHARMACOKINETIC (PK) AND EXPOSURE-RESPONSE (ER) ANALYSES RESULTS OF ABBV-085, AN ANTIBODY DRUG CONJUGATE (ADC), IN PATIENTS WITH ADVANCED SOLID TUMORS.

著录项

相似文献

相关主题

期刊订阅